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The fibroblast growth factor receptor tyrosine
kinases (FGFR1, 2, 3, and 4) represent promising
therapeutic targets in a number of cancers. We
have developed the first potent and selective irre-
versible inhibitor of FGFR1, 2, 3, and 4, which we
named FIIN-1 that forms a covalent bond with
cysteine 486 located in the P loop of the FGFR1
ATP binding site. We demonstrated that the inhibitor
potently inhibits Tel-FGFR1-transformed Ba/F3 cells
(EC50 = 14 nM) aswell as numerous FGFR-dependent
cancer cell lines. A biotin-derivatized version of the
inhibitor, FIIN-1-biotin, was shown to covalently label
FGFR1 at Cys486. FIIN-1 is a useful probe of FGFR-
dependent cellular phenomena and may provide
a starting point of the development of therapeutically
relevant irreversible inhibitors of wild-type and
drug-resistant forms of FGFR kinases.
INTRODUCTION
In recent years, targeted therapy has attracted much attention in
the field of cancer therapeutics due to the high profile success of
inhibitors that target kinases that are aberrantly activated. One
validated approach involves targeting protein kinases, particu-
larly receptor tyrosine kinases, which reside at the apex of key
signal transduction pathways. There are 518 protein kinase
genes encoded in the human genome, many of which have
been observed to become constitutively activated by amplifica-
tion or mutation. Constitutive kinase activation can lead to an
oncogene-addicted state that renders cancer cells, but not
noncancerous cells, exquisitely sensitive to the inhibitors target-
ing the activated kinase. This observation has stimulated the
development of numerous small molecule kinase inhibitors tar-
geting kinases such as Bcr-Abl, mutant EGFR, V617F Jak-2,
FLT3-ITD, c-Kit, and PDGFR (Cohen et al., 2002; Ranson,
2002; Savage and Antman, 2002). To date, a dozen small mole-
cule kinase inhibitors have been approved for clinical use andChemistry & Biology 17, 2approximately 150 inhibitors are in various stages of clinical
development.
Small molecule kinase inhibitors can bind to kinases in
a reversible or an irreversible fashion. Reversible kinase inhibi-
tors have been extensively investigated and typically bind to
the ATP site with the kinase in an active (type 1) or an inactive
(type 2) conformation (Liu and Gray, 2006). Irreversible inhibitors
usually possess electrophilic functional groups such as
a,b-unsaturated carbonyls and chloro/fluoromethyl carbonyls
that react with the nucleophilic sulfhydryl of an active-site
cysteine (Zhang et al., 2009). High selectivity of irreversible inhib-
itors can be achieved by exploiting both the inherent noncova-
lent selectivity of a given scaffold and the location of a particular
cysteine residue within the ATP site. For example, the most
well-characterized, selective irreversible inhibitors of epidermal
growth factor receptor (EGFR) such as PD168393 (Fry et al.,
1998) were created by appending an acrylamide group to the 6
position of the 4-anilinoquinazoline scaffold, a pharmacophore
known to be EGFR selective, that undergoes Michael reaction
with a rare cysteine (Cys773) in the ATP binding site. However,
potential cross-reactivity with other kinases that contain a
cysteine at the equivalent position must be considered as re-
cently demonstrated by the cross-reactivity of covalent EGFR
inhibitors with Tec family kinases such as Bmx (Hur et al.,
2008). Irreversible inhibitors have been shown to overcome
drug resistance caused by mutation of the ‘‘gatekeeper’’ amino
acid, as has been observed for HKI-272, an irreversible EGFR
inhibitor, against the T790M EGFR mutant (Carter et al., 2005;
Kwak et al., 2005).
The fibroblast growth factor receptor (FGFR) family of receptor
tyrosine kinases consists of four family members, FGFR1–4,
which bind to 22 different FGF ligands (Koziczak et al., 2004).
FGF ligands mediate their pleiotropic actions by binding to
FGFRs that have intrinsic intracellular protein tyrosine kinase
domain. Upon dimerization, FGFRs can activate an array of
downstream signaling pathways, such as MAPK and PKB/Akt
pathways. FGF signaling appears to play critical roles not only
in normal development and wound healing but also in tumor
formation and progression (Powers et al., 2000). Germline-acti-
vating mutations in FGFRs have been found to be associated
with congenital skeletal disorders such as Pfeiffer syndrome,85–295, March 26, 2010 ª2010 Elsevier Ltd All rights reserved 285
Figure 1. Small Molecule Inhibitors of
FGFRs
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Irreversible Inhibitors of FGFR KinaseApert syndrome, Beare-Stevenson syndrome, hydrochondro-
plasia, achondroplasia, and SADDAN syndrome (Jang et al.,
2001; van Rhijn et al., 2001). Somatic mutations of FGFRs that
likely result in receptor gain of function are present in a variety
of cancers such as bladder cancer, gastric cancer, colorectal
cancer, endometrial carcinomas, cervical carcinoma, lung squa-
mous cell carcinoma, and hematopoietic diseases (Dutt et al.,
2008; Pollock et al., 2007). Interestingly some of the somatic
mutations identified in cancers are identical to known germline
mutations. These findings have been extended by recent
systematic sequencing of cancer genomes that has revealed
that the FGF signaling pathway displayed the highest enrichment
for kinases carrying non-synonymous mutations among 537
non-redundant pathways that were examined (Greenman
et al., 2007). Besides somatic mutations of FGFRs, amplification
and overexpression of FGFRs are also present in certain types
of human cancers such as breast cancer and prostate cancer
and are believed to be involved in tumorigenesis and cancer
progression (Devilard et al., 2006; Feng et al., 1997). Recently,
two genome-wide association studies identified single nucleo-
tide polymorphisms (SNPs) in FGFR2 as breast cancer suscep-
tibility loci (Hunter et al., 2007), and these SNPs were identified
as being linked to upregulated expression of FGFR2 (Meyer
et al., 2008). Therefore, FGFR signaling appears to be a plausible
target for both genetic diseases and cancers.
Over the last decade, efforts to discover small molecule FGFR
inhibitors have resulted in the discovery of several selective and
potent inhibitors that reversibly bind to the FGFR ATP binding
site. For example, the oxindole (SU5402) and the benzimidazole
(CHIR258) were reported to be inhibitors of FGFR, VEGFR, and
PDGFR (Figure 1) (Mohammadi et al., 1997; Trudel et al.,
2005). The inhibitor NP603 was designed as a hybrid of FGFR
inhibitors SU6668 and PD173074 and inhibits FGFR1 with an
IC50 of 0.4 mM (Kammasud et al., 2007). CHIR258 is currently
in phase I clinical trials for treatment of AML, multiple myeloma,
and malignant melanoma. However, the in vivo efficacy of these
reversible FGFR inhibitors is limited by their rapid blood clear-
ance, and therefore there is a compelling need for irreversible
FGFR inhibitors with suitable pharmacokinetic properties.
To date, no irreversible inhibitors of FGFR kinases have been286 Chemistry & Biology 17, 285–295, March 26, 2010 ª2010 Elsevier Ltd All rights reservedl
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freported. Here we describe the synthesis
and characterization of an irreversible
inhibitor of FGFRs that forms a cova-
lent bond with a conserved cysteine
(Cys486 of FGFR1) located at the rim of
the P loop.
RESULTS
Design of an Irreversible FGFR
Inhibitor, FIIN-1
We initiated our design efforts using the
pyrimidopyridine PD173074 (Figure 1)
as a lead structure, because bindingassays with 317 kinases (see Table S1 available online) demon-
strated a selectivity of PD173074 for FGFRs and its co-crysta
structure with FGFR1 is available (Mohammadi et al., 1998)
Analysis of the crystal structure and comparison to related
compounds that inhibit PDGFR, Src, and Abl suggest that the
3,5-dimethoxyphenyl group of PD173074 is essential for FGFR
kinase selectivity. We determined that Cys486 in the P loop o
FGFR1, which was mutated to an alanine in the FGFR1 crysta
structure (PDB ID: 2fgi), is located approximately 10 A˚ away
from the pyridine nitrogen of PD173074 (Figure 2B). We decided
to attach a phenyl group bearing a meta-acrylamide to the
1-nitrogen of the pyrimido[4,5]pyrimidine, another well-charac-
terized ATP-competitive tyrosine kinase inhibitor template
(Figure 2A) (Su et al., 1986). The resulting compound 1 was
demonstrated to bind to FGFRs and exhibited a good selectivity
when tested against a panel of 402 kinases. Unfortunately, the
compound was only able to inhibit cellular FGFR1 kinase activity
as measured by a Tel-FGFR1-transformed Ba/F3 cell prolifera-
tion assay, with a 50% inhibitory concentration (EC50) o
1.5 mM. This potency was insufficient for this compound to be
used as a cellular probe of FGFR kinase function. The approxi-
mately 300-fold loss of cellular activity of compound 1 relative
to PD173074 suggested that replacement of the t-butylurea
functionality with the phenylamide moiety of 1 was deleterious
to the activity and that a covalent bond with Cys486 was mos
likely not formed.
We next introduced a one-carbon spacer to make the corre-
sponding benzylamino analog 2, which resulted in a compound
that possessed an EC50 of 400 nM against cellular Tel-FGFR1
kinase activity. A modeling study indicated that the b carbon o
the acrylamide is positioned 2.9 A˚ away from Cys486, an idea
distance for covalent bond formation (Figure 2B). We noticed
that both 2,6-dichlorophenyl group and 3,5-dimethoxypheny
groups were used as substituents to occupy the hydrophobic
region in the ATP binding site (Hamby et al., 1997). We decided
to combine the 2,6-dichloro and the 3,5-dimethoxy functional-
ities in an effort to obtain greater potency and selectivity
for FGFR kinases (Hamby et al., 1997; Ding et al., 2006). The
resulting compound that we named FIIN-1 (FGFR irreversible
inhibitor-1; Figure 2A), blocked proliferation and survival o
Figure 2. Design of Irreversible FGFR Inhibitor FIIN-1
(A) Chemical structure of PD173074 and design of its irrevers-
ible analog FIIN-1.
(B) Crystal structure (PDB ID: 2fgi) showing the location of the
unique cysteine (Cys486) in FGFR1 relative to the binding site
of the PD173074 inhibitor (left). Amodel of bindingmode of the
compound 2 within FGFR1 active site (right) demonstrates
a proper distance for covalent bond formation between the
electrophilic center of the compound and Cys486.
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EC50 of 14 nM and 10 nM, respectively. To investigate the func-
tional importance of the acrylamide substituent, we synthesized
FRIN-1 (FGFR reversible inhibitor-1; Figure 2A) where the acyla-
mide is replaced with a propyl amide that is incapable of forming
a covalent bond with Cys486. FRIN-1 is 24-fold less potent
against Tel-FGFR1 (EC50 = 340 nM) and 100-fold less potent
against Tel-FGFR3 (EC50 = 1040 nM)-transformed Ba/F3 cells,
demonstrating the functional importance of the acrylamide
functionality. Assay of recombinant FGFR1 measured in Z0-lyte
format (Rodems et al., 2002) demonstrated that FIIN-1 is approx-
imately 2.3 times more potent than FRIN-1 in vitro, supporting
that the additional activity is attributed to the irreversible modifi-
cation (Figure S1).
FIIN-1 Is a Potent, Selective FGFR Inhibitor
We next sought to investigate the selectivity of FIIN-1 and
FRIN-1 for FGFR family kinases on a kinome-wide level. Both
FIIN-1 and FRIN-1 were profiled against a panel of 402 different
kinase binding assays using the Ambit KinomeScan technology
at a concentration of 10 mM (Karaman et al., 2008). The score
indicates the percentage of kinases that retained binding to solid
matrix after competition with the inhibitor. Therefore, a lower
score for a kinase implies tighter binding of the inhibitor to the
kinase. FIIN-1 bound to several kinases including FGFR1-4,
Flt1, Flt4, and VEGFR (Table 1; Table S1). Kinases that were
displaced to greater than 90% of the DMSO control were con-
sidered ‘‘strong’’ hits and were further examined in a dose-
response format to determine dissociation constants (KD’s).
The potent association of FIIN-1 to FGFRs was confirmed with
KD’s of 2.8, 6.9, 5.4, and 120 nM for FGFR1, 2, 3, and 4, respec-
tively. Only two other kinases associated with FIIN-1 with KD’sChemistry & Biology 17, 285–295, Marchbelow 100 nM were Blk (KD = 65 nM) and Flt1
(KD = 32 nM). The biochemical IC50 values of
FIIN-1 using the Z0-lyte assays were determined
to be 9.2, 6.2, 11.9, and 189 nM against FGFR1,
2, 3, and 4, respectively, and are in an excellent
agreement with the measured KD values. The
IC50’s for Blk and Flt1 that bound less tightly with
FIIN-1 were 381 nM and 661 nM, respectively,
indicating a moderate inhibition. This good correla-
tion between KD and IC50 values underscores that
the observed binding with kinases translates into
the inhibition of kinases. Together, the results
from binding and activity assays suggest that
FIIN-1 is a selective FGFR inhibitor at a biochemical
level and also demonstrated its selectivity over
other kinases such as c-Src, TNK1, and YES thathave a P loop cysteine at the same position as the FGFRs (Zhang
et al., 2009).
Interestingly, unlike in vitro kinase assay and cellular assay
where the irreversible inhibitor FIIN-1 was considerably more
potent than the reversible inhibitor FRIN-1, both compounds ex-
hibited similar scores at the 10 mM screening concentration and
similar KD values in the kinase binding assays. It is unlikely that
the acrylamide group of FIIN-1 was inactivated by dithiothreitol
(6 mM) contained in the binding assay buffer, because the
potency (IC50) of FIIN-1 and FRIN-1 for FGFR1 was unaffected
by 6 mM dithiothreitol in vitro (Figure S1). This suggests that
the majority of binding energy of FIIN-1 comes from noncovalent
binding interactions.
To further examine the selectivity of FIIN-1, we profiled the
compound using a panel of various tyrosine kinase-transformed
Ba/F3 cells (Melnick et al., 2006). FIIN-1 was not cytotoxic
toward wild-type (WT) Ba/F3 cells (EC50 > 10 mM) and was barely
active against Bcr-Abl (EC50 > 10 mM), NPM-Alk (EC50 > 10 mM),
Tpr-Met (EC50 > 10 mM), Tel-Arg (EC50 > 10 mM), Tel-Blk (EC50 =
2 mM), Tel-Bmx (EC50 = 2 mM), Tel-Jak2 (EC50 = 5 mM), and
Tel-Jak3 (EC50 > 10 mM). The observed low activity against
Tel-Blk, Bmx, and Jak3, which contain a reactive cysteine in
the ribose binding region further confirms selectivity of FIIN-1.
A Biotin-Labeled FIIN-1
In order to demonstrate covalent binding of FIIN-1 to FGFR
kinases, we synthesized a biotinylated version of FIIN-1
(FIIN-1-biotin; Figure 3A) where a biotin is tethered via a flexible
polyethylene glycol linker at the other end of the electrophilic
acrylamide group. This design was implemented because
molecular modeling suggested that this linker would be directed
out of the ATP binding cleft and toward solvent. As has been26, 2010 ª2010 Elsevier Ltd All rights reserved 287
Table 1. Profiling of FGFR Inhibitors for Binding with a Panel
of 402 Kinases
FIIN-1 (10 mM) FRIN-1 (10 mM) PD173074 (1 mM)
Kinases Score KD (nM) Score KD (nM) Score KD (nM)
BLK 0.5 65 15 2300
CAMK1D 3.4 15
CSF1R 0.2 0.25
DDR1 0.1 0.2
EPHB6 1.4 0.9
ERK5 0.05 160 0 130
FGFR1 0 2.8 0 3.1 0.4
FGFR2 2.1 6.9 2.4 5.6 2.9
FGFR3 1.8 5.4 1.4 5.4 0.05
FGFR4 0.1 120 0.25 280 17
FLT1 0.3 32 0.55 49 8
FLT4 0.2 120 2 340 6
FRK 6 9.2
HPK1 5.8 10
JAK3 6.4 No binding
KIT 1.2 420 0.55 250
LCK 0.7 0.6
MAP3K2 1.6 1.8
MAP3K3 0.5 0.65
MAP4K3 0.85 11
MAP4K5 0.2 2.7
MET 5.5 1000 11 1400
MST1 6.6 33
MST3 4.6 4.6 7
MST4 2.6 1.6
PDGFRB 2.4 480 2.6 480 38
TAO1 0 0
TAOK1 0.2 0.2
TAOK3 0.15 0.1
TIE1 5.2 6.4
TIE2 5.6 6.8
VEGFR2 1.9 210 5 470 21
Kinases that were displaced by inhibitors to greater than 90% of the
DMSO control (Ambit score <10) from KinomeScan platform binding
assays for 402 different kinases are listed. KD values were also measured
for selected kinases. See Table S1 for a complete list.
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thylaminomethyl moiety can be appended to the terminal olefin
without disrupting the ability of the compound to function as a
Michael acceptor (Tsou et al., 2005). The dimethylaminomethyl
functionality has also been suggested to enhance reactivity
toward the nucleophilic thiol by acting as a general base catalyst.
As a control for binding reversibility, we also synthesized a bioti-
nylated FRIN-1 (FRIN-1-biotin; Figure 3A), which lacks the
electrophilic center. The cellular EC50 of FIIN-1-biotin against
Tel-FGFR1,3-transformed Ba/F3 cells was determined to be
35 nM and 54 nM, respectively, which is comparable to the
parent compound FIIN-1 and demonstrates that the biotin modi-
fication did not significantly affect the potency or cell perme-288 Chemistry & Biology 17, 285–295, March 26, 2010 ª2010 Elsevieability. To determine whether FIIN-1-biotin could covalently label
FGFR1 in cells, HEK293 cells were transiently transfected with
a full-length FGFR1 expression vector and were treated with
each biotin probe (50 mM) for 2 hr, after which cell lysates were
subjected to immunoprecipitation with an anti-FGFR1 antibody.
Probing the blot with streptavidin-HRP revealed that FGFR1 was
labeled by the FIIN-1-biotin, not by FRIN-1-biotin (Figure 3B).
The biotinylated covalent inhibitor was used to study the
kinetics of covalent modification of FGFR1. Recombinant
FGFR1 kinase domain was pre-incubated with FIIN-1-biotin
(250 nM) for various times (0–60min), and both the in vitro activity
and labeling of FGFR1 were measured after the kinase reaction
was allowed to proceed for 1 hr (Figure S2A). As expected
for a covalent inhibitor, increasing the pre-incubation time with
FIIN-1-biotin resulted in increased labeling of FGFR1 and a corre-
lated loss of FGFR1 enzymatic activity, consistent with covalent
modification being responsible for kinase inactivation. Then we
compared the kinetics of FIIN-1 with FRIN-1 (100 nM) using a
similar kinetic experiment with FGFR1 (Figure S2B). The result
indicates a more rapid inhibition by FIIN-1 than FRIN-1, suggest-
ing that irreversible modification contributes to rapid kinase inhi-
bition. In addition, an in vitro time course study for a longer period
(0–24 hr) demonstrated that FGFR1 is gradually modified by
FIIN-1-biotin, reaching a plateau after approximately 24 hr
(Figure S2C).
FIIN-1 Irreversibly Blocks Both Activation of FGFR
and Its Downstream Signals
To confirm that FIIN-1 is capable of inhibiting FGFR1 signaling,
we used an inducible FGFR1 (iFGFR1) system where oligomeri-
zation and activation of FGFR1 are induced upon the treatment
of a small molecule AP20187 (Welm et al., 2002). The iFGFR1
construct contains an N-terminal myristylation sequence, an
FGFR1 kinase domain, two tandem domains of F36V mutant
FKBP12 (FKBPv), and a C-terminal hemagglutinin (HA) epitope.
A stable MCF10A mammary epithelial cell line expressing
iFGFR1 construct was made through retroviral transfection and
selection with puromycin. The bivalent compound AP20187
exhibits high affinity for the FKBPv domain and induces dimer-
ization and autophosphorylation of the fused FGFR1 kinase
domains, which in turn triggers activation of downstream
signaling pathways. Serum-starved MCF10A cells that stably
express iFGFR1 were treated with 20 nM of either FIIN-1 or
PD173074 as a control for 30 min in the presence or absence
of AP20187 (100 nM). The cell lysates were immunoprecipitated
with anti-HA antibody and the level of iFGFR1 autophosphoryla-
tion was examined using anti-phosphotyrosine antibody. Both
compounds at a concentration of 20 nM almost completely
blocked activation of iFGFR1 and phosphorylation of down-
stream effectors Erk1/2 (Figure 3C).
We next examinedwhether FIIN-1 inhibits iFGFR1 activation in
an irreversible manner. Serum-starved MCF10A cells were
treated with FIIN-1 or PD173074 (2 or 20 nM) for 30 min, exten-
sively washed with PBS, and maintained in serum-free condi-
tions for 6 hr prior to activation of iFGFR1 by AP20187. Indeed,
FIIN-1 at 20 nM sustained the inhibition of phosphorylation of
both iFGFR1 and Erk1/2 even after washout of the drug, while the
inhibitory activity of the reversible inhibitor PD173074 at 20 nM
was almost completely eliminated by the washout procedurer Ltd All rights reserved
Figure 3. FIIN-1 Irreversibly Inhibits FGFR1 and Its Downstream Signaling
(A) Structures of biotin-tethered inhibitors (FIIN-1-biotin and FRIN-1-biotin).
(B) FIIN-1-biotin labeled full-length FGFR1 ectopically expressed in HEK293 cells.
(C) MCF10A cells that stably express iFGFR1 were serum starved for 1 day and were stimulated by AP20187 for 30 min in the presence or absence of 20 nM of
the inhibitors. Western blot analysis using immunoprecipitated iFGFR1 and total cell lysates showed that both PD173074 (20 nM) and FIIN-1 (20 nM) inhibited
iFGFR1 autophosphorylation and its downstream Erk1/2 almost completely.
(D) Serum-starved iFGFR1 MCF10A cells were treated with inhibitors for 30 min, extensively washed, and incubated in a serum-free condition for 6 hr prior to
iFGFR1 activation. Washout did not affect FIIN-1’s (20 nM) ability to inhibit FGFR1, but eliminated the inhibitory activity of PD173074 (20 nM).
(E) The lysates from MCF10A cells that stably express either WT or C486S iFGFR1 were mixed with the biotin probes (5 mM). Streptavidin-HRP blot of
immunoprecipitated iFGFR1 revealed that FIIN-1-biotin labeled WT iFGFR1, but barely labeled C486S iFGFR1.
(F) WT or C486S iFGFR1 MCF10A cells were pre-treated with FIIN-1 or FRIN-1 for 1 day in a serum-free condition and were stimulated with AP20187 for 2 min.
FIIN-1 inhibited autophosphorylation of WT iFGFR1 with about five times higher potency compared to FRIN-1.
(G) Serum-starvedMCF10A cells were treatedwith various doses of inhibitors along with AP20187 for 2 days. Viability of cells was assessed bymeasuring cellular
ATP level. FIIN-1 blocked iFGFR1-dependent proliferation of MCF10A cells with 10-fold higher potency than FRIN-1. Moreover, FIIN-1 and FRIN-1 blocked the
proliferation of C486S iFGFR1 MCF10A cells with a similar potency. Error bars indicate standard deviation from duplicate samples.
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Figure 4. FIIN-1 Abrogates the Effects of iFGFR1 Activation in
iFGFR1-Transformed MCF10A Cells in 3D Culture
(A) PD173074 (1 mM) and FIIN-1 (20 nM) inhibited abnormal morphogenesis
induced by iFGFR1 activation.
(B) Both inhibitors abolished iFGFR1-mediated Akt phosphorylation (Ser473)
and (C) iFGFR1-mediated cell growth and luminal cell survival in 3D culture.
Neither drug was toxic to the outer layer of cells in 3D culture.
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FGFR1 in an irreversible manner. Likewise, a similar washout
experiment with FRIN-1 demonstrated that the FGFR1 and
downstream Erk1/2 inhibition occurred in a reversible fashion
(Figure S3).
In order to examine if Cys486 of FGFR1 is labeled by FIIN-1 in
cells, we generated a C486S mutant iFGFR1 construct and
produced a stable MCF10A cell line expressing C486S iFGFR1
using retroviral transduction. MCF10A cells that stably express
eitherWT or C486S iFGFR1were lysed, incubated with the biotin
probes (5 mM each) for 1 hr, and immunoprecipitated with an
anti-HA antibody. The blot with streptavidin-HRP showed that
FIIN-1-biotin strongly labeled WT iFGFR1, but barely labeled
C486S iFGFR1 (Figure 3E). This result confirms that Cys486 is
the primary labeling site of FIIN-1.
We next investigated the functional implication of covalent
modification of Cys486 on FGFR1 inhibition. Serum-starved
iFGFR1 MCF10A cells were treated with increasing doses of
the inhibitors before stimulus with AP20187 and examination of
FGFR1 autophosphorylation (Y653/Y654) status. Intriguingly,
when the inhibitors were pre-treated for 10 or 30 min, FIIN-1
and FRIN-1 inhibited autophosphorylation with almost equiva-
lent potency (data not shown). However, when inhibitors were
pre-treated for a long term (24 hr), which the in vitro studies
suggest is sufficient time to lead to almost complete labeling
(Figure S2B), FIIN-1 exhibited an approximately 5-fold greater
potency compared to FRIN-1 (Figure 3F). We then compared
activity of the inhibitors for iFGFR1-dependent cellular prolifera-
tion. WT and C486S iFGFR1 MCF10A cells were serum starved
and treated with AP20187 and FIIN-1/FRIN-1 for 2 days in a
serum-free condition, and cell proliferation was measured
(Figure 3G). Indeed, FIIN-1 inhibited the proliferation of WT cells
(EC50 = 2.7 nM) ten times more potently than FRIN-1 (EC50 =
29 nM). As expected, the C486S iFGFR1 cells, which are resis-
tant to covalent labeling, were inhibited by FIIN-1 (EC50 = 20 nM)
and FRIN-1 (EC50 = 23 nM) with equivalent potency. These
biochemical and cellular experiments demonstrate that the
ability to covalently modify Cys486 of FGFR1 contributes to
the improved potency of FIIN-1 relative to FRIN-1 despite both
compounds being potent FGFR1 inhibitors without covalent
bond formation.
FIIN-1 Abolishes iFGFR1-Mediated Mammary Epithelial
Cell Transformation in 3D Culture
MCF10A cells grown in three dimensions (3D) recapitulate
several features of mammary epithelium in vivo (Schmeichel
and Bissell, 2003; Shaw et al., 2004) and have been used as a
unique system to study the signaling pathways involved in the
early progression of breast cancer (Debnath et al., 2003;
Muthuswamy et al., 2001; Radisky et al., 2001). Wild-type
MCF10A cells form spherical structures that consist of an outer
layer of polarized, growth-arrested epithelial cells surrounding
a hollow lumen. Activation of iFGFR1 in MCF10A cells resulted
in cellular transformation and formation of the large and disorga-
nized structures inMatrigel, similar to that observed previously in
the iFGFR1-activated mouse mammary HC11 cell line (Xian
et al., 2007). To investigate the effects of FIIN-1 on FGFR1-medi-
ated transformation of mammary epithelial cells in a more phys-
iologically relevant context, we first examined the morphology of290 Chemistry & Biology 17, 285–295, March 26, 2010 ª2010 ElsevieiFGFR1-activated cells in 3D culture in the absence or presence
of FIIN-1 and PD173074 (Figure 4A). The abnormal morphogen-
esis induced by iFGFR1 activation was prevented by the treat-
ment of either FIIN-1 (20 nM) or PD173074 (1 mM). Moreover,
iFGFR1 activation-induced Akt phosphorylation and luminal
cell survival were also abolished by either FIIN-1 or PD173074,
as assessed by immunostaining with antibodies against phos-
pho-Akt (Figure 4B) and activated caspase 3 (Figure 4C). Impor-
tantly, neither FIIN-1 nor PD173074 affected the growth of WT
MCF10A cells, suggesting that FGF signaling is dispensable to
normal mammary epithelial cells and inhibition of FGF pathway
in cancer might be effective and selective to inhibit cancer cell
growth with low toxicity to noncancerous cells.r Ltd All rights reserved
Table 2. Antiproliferative Activity of FIIN-1 Against Various Cancer Cell Lines
Cell Line Organ
500K SNP array copy number EC50 (mM)
FGFR1 FGFR2 FGFR3 PD173074 FIIN-1
KATO III Stomach 2.18 14.95 1.76 0.022 0.014
RT4 Bladder 2.1 1.71 1.73 0.05 0.07
SNU-16 Stomach 1.71 15.14 1.25 0.12 0.03
STS-0421 Muscle NA NA NA 0.12 NA
G-401 Kidney 1.94 1.95 1.93 0.21 0.14
SBC-3 Lung 2.44 1.81 1.88 0.32 0.08
A2.1 Pancreas NA NA NA 0.34 0.23
A2780 Ovary 1.94 2 2.14 0.82 0.22
FU97 Stomach 1.89 1.72 1.75 1.16 0.65
G-402 Kidney 1.89 1.91 1.91 2.48 1.65
R082-W-1 Thyroid 2.46 1.68 1.87 2.5 >5
LU99A Lung 2.07 2.08 1.62 3 >5
RD-ES Bone NA NA NA >5 2.3
PA-1 Ovary NA NA NA >5 4.6
JAR Choriocarcinoma NA NA NA >5 >5
H520 Lung NA NA NA >5 4.5
VM-CUB1 Bladder 2.01 2.05 1.7 >5 >5
NCI-H1703 Lung 4.19 1.73 1.8 >5 >5
JHH-7 Liver 1.33 1.84 1.85 >5 >5
TOV-112D Ovary NA NA NA >5 >5
Cell viability was measured using Syto-60 staining method following treatment of inhibitors for 72 hr. Cells are ranked according to their EC50 for
PD173074. Copy numbers for FGFR1, 2, and 3 genes in each cell line are also shown. Copy number changes were derived from a 500K SNP array
(diploid 2). NA, not available.
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Cancer Cell Lines
We screened 687 human cancer cell lines and identified the
cancer cell lines that were uniquely sensitive to PD173074 (Table
S2) and were therefore presumed to be dependent on FGFR
signaling for their survival (McDermott et al., 2007). We re-tested
a subset of the sensitive and resistant cell lines with a range of
concentrations of PD173074 and FIIN-1, by measuring cell
viability after 72 hr. As expected, FIIN-1 was capable of inhibiting
the viability of cell lines that had been shown to be sensitive to
PD173074 (Table 2). In general, FIIN-1 inhibited proliferation of
these cell lines at lower concentrations than PD173074. These
results suggest that FIIN-1 will be a valuable probe to identify
cancer cell lines that are sensitive to the inhibition of FGFR
kinase activity.
We examined the effect of FIIN-1 on cell survival and down-
stream pro-survival signaling pathways in the KATO-III and
SNU-16 gastric cancer cell lines (Figure 5A). These two cell lines
harbor FGFR2 gene amplification and have previously been
shown to be dependent of FGFR2 activation for their survival
(Kunii et al., 2008; Takeda et al., 2007). FIIN-1 potently sup-
pressed the pro-survival Akt and Erk1/2 pathways in both of
these cell lines. FGFR2 gene amplification in these cancer cell
lines resulted in an oncogene-addicted state that rendered cell
proliferation hypersensitive to the FGFR inhibitors (Table 2).
Interestingly, FIIN-1 also inhibited cell survival and survival
pathways in other cell lines such as A2780 and SBC-3 cells
that have not previously been shown to be dependent on theChemistry & Biology 17, 2FGFR family for survival (Figure 5A). This may indicate a role
for targets of FIIN-1 other than FGFRs. We performed a strepta-
vidin pulldown experiment using the extracts of MCF10A cells
that express iFGFR1 and identified a number of intracellular
proteins bound to FIIN-1-biotin using mass spectrometry anal-
ysis (Figure S4). A subset of the identified proteins (Table S3)
could be related to FGFR-independent pro-survival pathways,
but more in-depth study on the drug-sensitivity of these partic-
ular cell lines is currently under investigation.
Cancer-associated FGFR2 mutations have been identified in
endometrial carcinoma by high-throughput DNA sequencing
(Dutt et al., 2008). We investigated whether cell lines bearing
these mutations were sensitive to growth inhibition by FIIN-1.
Indeed, MFE-296 and AN3CA endometrial carcinoma cell lines
harboring activating FGFR2 mutations (N549K or N549K/
K310R) presented sensitivity (submicromolar EC50 values) to
FIIN-1, FRIN-1, and PD173074 in cell proliferation assays,
whereas Hec-1B cells that express WT FGFR2 were not sensi-
tive to all three FGFR inhibitors (Figure 5B). These results indicate
that FIIN-1 is also an effective agent against cancer cells that are
‘‘oncogene addicted’’ as a result of FGFR2 mutations.
FIIN-1 Weakly Inhibits FGFR1 Gatekeeper
Mutant V561M
Many patients being treated with small molecule kinase inhibi-
tors develop resistance to the therapy primarily as a result of
mutations that prevent efficient kinase inhibition. For example,
resistance to reversible EGFR inhibitors gefitinib and erlotinib85–295, March 26, 2010 ª2010 Elsevier Ltd All rights reserved 291
Figure 5. FIIN-1 Inhibits FGFR2 and Prosur-
vival Signaling Pathways and Inhibits
FGFR2-Dependent Cell Growth
(A) FIIN-1 inhibited prosurvival signaling pathways
in the FGFR2-amplified gastric cancer cell lines
includingKATOIII andSNU-16and in theother can-
cer cell lines thatwere previously shown to be inde-
pendent of FGFR signaling for survival. Cells were
treated for 6 hr with 200 nM of each compound.
(B) Proliferation of the endometrial carcinoma cell
lines (MFE-296 and AN3CA) that express acti-
vating FGFR2 mutants were abrogated by FGFR
inhibitors, while Hec-1B cells that express WT
FGFR2 showed no sensitivity to the inhibitors.
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a result of mutations in EGFR kinase domain, particularly by
the gatekeeper mutation T790M (Pao et al., 2005). The gate-
keeper position also appears to be a hotspot for mutation in
Bcr-Abl, c-Kit, and PDGFR (Branford et al., 2002). Mutation of
the gatekeeper position can severely interfere with inhibitor
binding in the ATP site of kinase while still maintaining normal
or enhanced kinase function. It has been reported that irrevers-
ible EGFR inhibitors such as HKI-272 that targets Cys773 can
inhibit the T790M gatekeeper mutant (Carter et al., 2005; Kwak
et al., 2005; Yun et al., 2008). We therefore investigated whether
FIIN-1 inhibits the V561M gatekeeper mutant of FGFR1, which
has been reported to induce resistance to PD173074 (Figures
6A and 6B) (Blencke et al., 2004). HEK293 cells were transiently
transfectedwith full length of eitherWT FGFR1 or V561MFGFR1,
and autophosphorylation of both receptors was examined
following 1 hr drug treatment. Interestingly, the V561M FGFR1
mutation results in a higher level of FGFR1 autophosphorylation
relative to WT FGFR1. The activating nature of the gatekeeper
mutation has recently been documented for several other
kinases including c-Src, PDGFR, and c-Abl (Azam et al., 2008).
Concentrations up to 10 mM of PD173074 were incapable of
inhibiting autophosphorylation of FGFR1-V561M in agreement
with published results. This resistance likely results from a steric
clash between the dimethoxylphenyl ring of PD173074 and the
gatekeeper position (Figures 6C and 6D). In contrast, FIIN-1
effectively blocked autophosphorylation of FGFR1-V561M at
a concentration of 10 mM. This result demonstrates that covalent
inhibition of FGFR1 potentially overcomes the V561M mutation,
which is expected to arise when reversible FGFR inhibitors enter
clinical development. But the relatively low potency on V561M
also argues that FIIN-1 needs to be further optimized to become
a potent V561M FGFR1 inhibitor.
DISCUSSION
Using a structure-guided approach, we have developed a highly
potent and selective irreversible inhibitor of FGFRs, FIIN-1, that292 Chemistry & Biology 17, 285–295, March 26, 2010 ª2010 Elsevier Ltd All rights reservedis capable of forming a covalent bond
with a conserved cysteine located in the
P loop. FIIN-1 exhibited a high degree of
selectivity when tested against a panel
of 402 kinases with sub-500 nM dissocia-
tion constants only observed for FGFR1-4, Flt1, Flt4, and VEGFR kinase. FIIN-1 blocked autophosphory-
lation of FGFR1 and the phosphorylation of FGFR’s downstream
effectors Erk1/2 in MCF-10A cells that stably express iFGFR1
and repressed the proliferation of FGFR1,3-transformed Ba/F3
cells with an EC50 of 14 and 10 nM, respectively. Four lines of
evidence were provided to support the claim that FIIN-1 forms
a covalent bond with Cys486 of FGFR1. First, the corresponding
reversible inhibitor FRIN-1 lost 24-fold and 100-fold activity
against cellular Tel-FGFR1 and 3 kinase activity, respectively.
Second, the biotin-modified analog FIIN-1-biotin but not its
reversible analog FRIN-1-biotin is capable of labeling FGFR1
from cell lysates. Third, FIIN-1 maintains inhibition of FGFR1
kinase autophosphorylation and downstream signaling following
washout of the drug, whereas the reversible inhibitor FRIN-1
does not. Fourth, the C486S mutant of iFGFR1 is covalently
labeled by FIIN-1-biotin very weakly and cells bearing this muta-
tion are more weakly inhibited by FIIN-1 relative to WT iFGFR1
expressing cells.
Recent findings have highlighted the role of activating muta-
tions, amplifications, and overexpression of FGFRs in the patho-
genesis of a variety of human tumors includingmultiplemyeloma,
breast, prostate, colon, bladder, and endometrial cancers (Dutt
et al., 2008; Hunter et al., 2007; Jang et al., 2001; Pollock et al.,
2007; Powers et al., 2000; van Rhijn et al., 2001). These findings
have stimulated the development of reversible FGFR inhibitors as
potential therapeutics as exemplified by CHIR258, XL228, and
XL999, which are currently in clinical trials for several cancers.
Although no kinase inhibitor-resistant mutations have been
reported for FGFRs from clinical samples, analogy to other
kinases suggests that mutations at the gatekeeper position can
be anticipated. Our results suggest that irreversible FGFR inhib-
itors could overcome gatekeeper mutations such as V561M
similar to what has been observed for irreversible inhibitors of
the T790MEGFRgatekeepermutant. However, further optimiza-
tion of FIIN-1 will be required to obtain an inhibitor with a useful
level of potency against the V561M mutant.
The methods used to develop irreversible FGFR inhibitors are
likely to be generally applicable to many kinases with cysteine
Figure 6. FIIN-1 Moderately Inhibits V561M Mutant of FGFR1
(A and B) Dose-response inhibition of autophosphorylation ofWT (A) and V561M (B)mutant of full-length FGFR1 by PD173074 and FIIN-1. FIIN-1 (10 mM) inhibited
V561M FGFR1, whereas PD173074 (10 mM) that was nearly equipotent with FIIN-1 against WT FGFR1 was inactive to the mutant.
(C) Binding mode of PD173074 within V561M FGFR1.
(D) Molecular model of FIIN-1 bound to V561M FGFR1.
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covalent recognition of an active site to obtain selectivity
between all kinases that have a cysteine at a given position
and (b) covalent bond formation to get specificity relative to
the rest of the kinome. By appending the electrophiles that target
particular cysteines, a remarkable selectivity can be also
achieved. A similar approach has been previously used to
make selective inhibitors of EGFR (Fry et al., 1998), Btk (Pan
et al., 2007), Rsk1,2 (Cohen et al., 2005), and the T790 mutant
of EGFR (Zhou et al., 2009). More than 200 different kinases,
which represent 35% of human kinome, have at least one
cysteine residue in the ATP binding site (Zhang et al., 2009),
suggesting the broad utility of this approach for developing
selective irreversible kinase inhibitors.
SIGNIFICANCE
Gain-of-function mutations in FGFRs caused by chromo-
somal translocation, gene fusion, and gene amplification
have been identified in a variety of human cancers including
myeloid tumors and breast cancers. Several FGFR inhibitors
have been developed as potential therapeutic agents and
some are being evaluated in clinical trials for cancer treat-
ment. So far, only reversible inhibitors of FGFRs have been
developed. This article reports the first irreversible inhibitor
of FGFRs, namely FIIN-1, with nanomolar IC50 values. BasedChemistry & Biology 17, 2on the structural information of PD173074 bound to FGFR1,
the irreversible analog FIIN-1 was created by incorporating
an acrylamide moiety that forms a covalent bond with
the Cys486 positioned in the P loop within the active site.
FIIN-1 exhibited nanomolar inhibition of FGFRs and, surpris-
ingly, showedmoderate or nearly no affinity to c-Fgr, LIMK1,
c-Src, TNK1, and YES that bear the identical cysteine in the
P loop. This remarkable selectivity toward FGFRs indicates
that the selectivity and potency of FIIN-1 was determined
primarily by noncovalent FGFR-drug interaction. The cova-
lent linkage resulted in the irreversible blockage of FGFR1
activation and its downstream signals, which could poten-
tially be advantageous in achieving efficacious in vivo action.
But, more notably, the ability of FIIN-1 to form a covalent
bond resulted in a moderate inhibition of the gatekeeper
mutant of FGFR1 that is resistant to the reversible inhibitor
PD173074. This result suggests that irreversible FGFR inhib-
itors such as FIIN-1 should be considered promising leads to
target FGFR mutants that may emerge in the clinic.EXPERIMENTAL PROCEDURES
In Vitro FGFR1 Activity Assay
Inhibitors were assayed against recombinant kinase domain FGFR1 using the
Z0-LYTE Enzymatic Kinase Assay format (Invitrogen). Assays were carried out
using 8 ng of FGFR1, 2 mMpeptide substrate, and 40 mMATP for 1 hr reaction.85–295, March 26, 2010 ª2010 Elsevier Ltd All rights reserved 293
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http://www.invitrogen.com/kinaseprofiling.
Washout Experiment
MCF10A cells expressing iFGFR1 were cultured in 100 mm dishes, and at
about 90% confluence, cells were serum starved for 1 day. Cells were then
incubated with FGFR inhibitors for 30 min, washed with PBS three times,
and maintained in serum-free condition for 6 hr. After which, cells were treated
with AP20187 (100 nM) in a serum-free media for 30 min and harvested.
The resulting lysates were analyzed for iFGFR1 autophosphorylation using
immunoblot and immunoprecipitation.
Cell Viability Assays
Cell viability of Tel-FGFR1 or 3-transformed Ba/F3 cells was determined using
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Prom-
ega) assay following the manufacturer’s procedure. Cells (40,000 cells,
100 ml/well) were seeded in media in a 96 well plate and treated with 1 ml of
each pre-diluted compound (3-fold, 12-point dilutions from 1 mM DMSO
stock) for 48 hr. After addition of MTT reagents, absorbance was measured
using SpectraMax M5 (Molecular Devices). Each test was duplicated. Cell
viability was calculated by Atreatment/ADMSO 3 100% (A represents the absor-
bance recorded at 570 nm).
All other Ba/F3 cells including WT Ba/F3 cells were engineered to express
luciferase and therefore their viability was measured using luciferase reporter
gene assay. Each Ba/F3 cell line (4,000 cells in 50 ml) were plated to white
384 well microtiter plates (Corning), and the preplated compounds were
transferred (300 nl) to the assay plates using a 384-pin transfer device. Each
data point was triplicated. After incubation for 48 hr in cell incubator, 25 ml of
BrightGlo (Promega) was added and luminescence was quantified using
Envision multilabel plate reader (PerkinElmer).
Proliferationof iFGFR1expressingMCF10Acellswasassessedbymeasuring
cellular ATP. Cells were serum starved for 1 day and seeded to 96 well plates
(100 ml, 20,000 cells per well). In the serum-free condition, cells were treated
with AP20187 and increasing concentrations of inhibitors for 2 days. An equal
volume of CellTiter-Glo Luminescent Cell Viability Assay (Promega) reagent
was added and luminescence signal was measured after 10 min.
MFE-296, AN3CA, and Hec-1B cells were treated with inhibitors on the
second day after plating 1000 cells. Cell survival was assessed 4 days later
using the WST-1 assay (Roche). Each data point represents the median of
six replicate wells for each tumor cell line and inhibitor concentration.
For all other cancer cell lines, Syto-60 staining method was used. Cells
(3000–4000 cells) were seeded on 96 well plates and incubated overnight.
Following drug addition, the plates were returned to the incubator for an
additional 72 hr. Each plate was fixed in 4% formaldehyde and washed with
distilled water, and 100 ml of 1:5000 Syto-60 fluorescent dye (Invitrogen) was
added for an additional 1 hr. Following a final wash with distilled water, each
plate was read on a SpectraMax M5 plate reader, and all values were
expressed as a fraction of the untreated control wells. EC50 values for all
viability assayswere calculated usingGraphPad Prism 4 (GraphPad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, three tables, and Supple-
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